Looking for a new broker?
Reviva Pharmaceuticals Holdings, Inc. stock is down -28.96% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 November’s closed higher than October. In the last 5 Unusual Options Trades, there were 3 CALLs, 2 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 29 Sep 13:48 | 20 Oct, 2023 | 5.00 | 17593 | ||
| 03 Oct 17:34 | 17 Nov, 2023 | 2.50 | 2138 | ||
| 30 Oct 16:14 | 19 Jan, 2024 | 7.50 | 606 | ||
| 30 Oct 16:27 | 17 Nov, 2023 | 5.50 | 456 | ||
| 02 Nov 13:57 | 17 Nov, 2023 | 10.00 | 381 |
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia. RP1208 that is in pre-clinical development studies for depression and obesity.
